Silo Pharma Inc. Anticipates Key Study Results for PTSD Treatment SPC-15

Silo Pharma Inc. (NASDAQ: SILO), a biopharmaceutical company in the developmental stage, has announced the imminent release of data from two pivotal preclinical studies concerning its leading candidate, SPC-15, a novel intranasal prophylactic aimed at enhancing stress resilience and preventing Post-Traumatic Stress Disorder (PTSD). The studies, which include IND-enabling GLP-compliant toxicology and toxicokinetic testing alongside a large animal safety study mandated by the FDA, are expected to yield results within the next 30 to 90 days. These findings are crucial for the company's planned Investigational New Drug (IND) application, potentially submitted by the end of the year, with a Phase 1 clinical trial on the horizon for 2026. Silo Pharma is leveraging the FDA's 505(b)(2) pathway to accelerate the development of SPC-15, a treatment that could fill a significant gap in PTSD therapeutics, a field that has not seen a new FDA-approved drug in nearly a quarter of a century.